|
Translational Science Interagency Fellowship
|
Training Initiative
|
FDA
|
NCATS
|
The Translational Science Interagency Fellowship (TSIF) program is jointly sponsored by NCATS and the U.S. Food and Drug Administration (FDA) and aims to provide training in both translational science and regulatory science. The common goal of NCATS and the FDA is to bring safe and effective drugs, regimens and devices from the bench to the bedside as quickly and efficiently as possible. To that end, fellows will be trained in preclinical translational science, technology development, and regulatory research and review.
|
|
Transplant Cancer Match Study
|
Research Initiative
|
HRSA
|
NCI
|
A study linking databases of US transplant recipients, donors, and waitlist candidates to multiple US cancer registries to evaluate the spectrum of cancer risk in transplant recipients.
|
|
Trial to Assess Chelation Therapy 2 (TACT2)
|
Research Initiative
|
CDC
|
NIDDK, NCCIH, NHLBI, NIEHS
|
TACT2 is a clinical trial to determine whether intravenous (IV) Na2EDTA chelation therapy with oral (by mouth) multivitamins will reduce the risk of major cardiovascular events (such as stroke and heart attack) in patients who have already had a heart attack and who also have type 2 diabetes.
|
|
Tribal Epidemiology Centers Program
|
Research Initiative
|
IHS, CDC
|
NIMHD, OD/DPCPSI/THRO
|
The Tribal Epidemiology Centers Program develops Epidemiology Centers and public health infrastructure for American Indian/Alaska Native communities.
|
|
Tribal Health Research Advisory Council (HRAC)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, CDC, HRSA, IHS, OS, SAMHSA
|
NIMHD, OD/DPCPSI/THRO
|
The National Institutes of Health (NIH) supports the activities of the Tribal Health Research Advisory Council (HRAC), including obtaining input from tribal leaders on health research priorities and needs, and dissemination of information.
|
|
Tularemia Animal Model Qualification Working Group
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, FDA
|
NIAID
|
This working group is collaborating on the qualification of a primate model of pneumonic tularemia under the Food and Drug Administration (FDA) Animal Model Qualification/Drug Development Tools Program. Animal model qualification is a regulatory decision and will be published on the FDA website when final. The collaboration includes the exchange of study data, study reports, and agreements on regulatory strategy for model qualification.
|
|
U.S. Burden of Health Disparities Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIMHD, NCI, NHLBI, NIA, OD/DPCPSI/OBSSR, ODP, NIAMS
|
Through this project, the U.S. Burden of Health Disparities Working Group at NIH aims to generate a landmark and comprehensive report and public platform with data on U.S. Burden of Health Disparities by Race/Ethnicity, Sex, Age, Socioeconomic Status and Geography. The project entails producing detailed county-level estimates of disease burden stratified by race/ethnicity, socioeconomic status (SES), age, and sex for a vast array of diseases, injuries and risk factors. The report would include a broad set of measures of the burden of disease (e.g., disability-adjusted life years and healthy life expectancy). This project would result in a platform for downloadable, publicly available data review and visualization tools for extracting information on these stratified analyses at the county-level for every U.S. county. CDC/NCVS is providing guidance on vital statistics data, algorithms and procedures used to generate life expectancy estimates, etc., by race/ethnicity.
|
|
U.S. FDA Medical Imaging Drugs Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
CC
|
The Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology and makes appropriate recommendations to the Commissioner of Food and Drugs.
|
|
Understanding and Identifying the Needs for Medical Devices
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCATS
|
The Institute of Medicine Rare Diseases and Orphan Products 2010 Report recommended that the Food and Drug Administration (FDA) and National Institutes of Health (NIH) perform an assessment of unmet devices needs, and determine the impediments, and options for overcoming these impediments. The assessment was completed and analyzed in 2017. A manuscript and report have been written and will be published soon. The assessment will document examples of compelling unmet needs across sections of medical specialties. Collaborating are the Office of Rare Diseases Research at National Center for Advancing Translational Science (NCATS), and the Office of Orphan Product Development and other parts of the FDA.
|
|
Unified Medical Language System Metathesaurus (UMLS)
|
Resource Development
|
AHRQ, CDC, CMS, FDA
|
NLM
|
The National Library of Medicine (NLM) Unified Medical Language System (UMLS®) facilitates the development of computer systems that behave as if they understand the meaning of the language of biomedicine and health. To that end, NLM produces and distributes the UMLS Knowledge Sources (databases) and associated software tools (programs) for use by system developers in building or enhancing electronic information systems that create, process, retrieve, integrate, and/or aggregate biomedical and health data and information, as well as in informatics research. By design, the UMLS Knowledge Sources are multi-purpose.
|